Poll Results

Which medical condition will benefit the most from digital therapeutics?

ADHD: 0%

Behavior and Mental Health: 62.5%

Diabetes: 25%

Gastrointestinal: 0%

Genitourinary: 0%

Musculoskeletal: 0%

Sleep: 0%

Substance Use Disorder: 0%

Wellness: 12.5%

Other: 0%

How soon will COVID-19 vaccines transition from government funded to commercially available?

Before the end of 2022: 12.5%

First half of 2023: 25%

Second half of 2023: 50%

2024 and beyond: 12.5%

Which term do you use to refer to the process of preparing a new product or NDC for listing in the drug pricing compendia?

Compendia Submission: 64%

New Product Information: 18%

Drug Database Addition: 9%

Drug Price Publication: 9%

Drug File Integration: 0%

Health IT Preparation: 0%

APhA supports the pharmacy profession through a variety of key advocacy issues. Of the following, which of these issues is a top priority for you?

Improving the COVID-19 Test to Treat Initiative: 9%

Pharmacist Provider Status: 61%

Eliminating DIR Fees: 30%

How quickly will the FDB Vela ePrescribing Network be a viable competitor in the market?

Immediately successful: 0%

Within 1 year: 10%

Within 2-5 years: 70%

More than 5 years: 10%

Will not be able to compete: 0%

Will have limited uptake: 10%

How have drug supply shortages in 2022 changed compared to shortages in 2021?

More products impacted: 44%

Same number of products impacted: 44%

Less products impacted: 11%

What factor will have the greatest impact on the number of unfilled pharmacist positions that currently exists?

2022 pharmacy school graduates will fill the open positions: 8.3%

Pharmacy closures will help reduce the number of unfilled positions: 58.4%

Currently employed pharmacists will see an increases in hours worked and overtime: 25.0%

Chains will reassign pharmacist administrators/HQ personnel back to the stores: 0.0%

Pharmacy schools will increase the incoming class size: 8.3%

Retired pharmacists will come out of retirement to fill hours: 0.0%

What impact will the Mark Cuban Cost Plus Drug Company Pharmacy have on drug prices in the next 2 years?

Retail pharmacies will lower their cash prices to compete: 10%

Select competing retail and internet pharmacies will lower their cash prices: 20%

Retail pharmacies will create or further enhance their own discount programs or clubs to compete: 20%

There will be an increase in discount card program utilization: 20%

No impact on pharmacy prices: 30%

What source will you rely on most to determine interchangeable biosimilar status?

FDA Purple Book: 91%

Pharmacy System and Compendia: 9%

PBM Formulary and Messaging: 0%

Pharmacist Knowledge and Education: 0%

Which stakeholder will have the most influence on the biosimilar dispensed from retail pharmacy?

PBM: 67%

Pharmacy: 17%

Biosimilar manufacturer: 8%

Physician: 8%

Patient: 0%

Wholesaler: 0%